China NMPA approves Harbour BioMed’s BLA for batoclimab injection to treat generalized myasthenia gravis: Cambridge, Massachusetts Saturday, October 24, 2026, 17:00 Hrs [IST] Ha ...

Whole-cell recordings and viral retrograde tracing in rats show that the interstitial nucleus of Cajal responds to ...

Harbour BioMed announced that the National Medical Products Administration (NMPA) of China has approved the Biologics License Application (BLA) for batoclimab injection (subcutaneous injection) ...

Laboratory electrophysiology, molecular simulations and mutational analysis identify an intersubunit transmembrane site ...

Clinically approved drugs induced ChAT expression and acetylcholine production in podocytes in vivo, suggesting the pathway could be pharmacologically targeted.

One-year results from the open-label extension of the phase III MINT trial presented at the American Association of ...

Exploratory phase 3 data suggest that gefurulimab may reduce the need for rescue therapy and hospitalizations in patients ...

Patients with gMG who lack detectable anti-AChR antibodies — a group historically excluded from clinical trials — show sustained benefits with efgartigimod.

Two people who watch the same movie may remember completely different scenes.One person remembers the words spoken by the ...

Prior to the autoinjector's approval, ZILBRYSQ was available as a self-administered prefilled syringe (PFS). Patients or their care partners will now have another portable treatment solution. The ...

<?xml encoding="utf-8" ?> The U.S. Food and Drug Administration (FDA) on Friday approved the first self-administered, once-daily, autoinjector administration option of UCB SA’s UCBJY UCBJF Zilbrysq ...